PTCL, NOS: An update on classification, risk-stratification, and treatment
The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains "not ot...
Saved in:
Published in | Frontiers in oncology Vol. 13; p. 1101441 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
09.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The peripheral T-cell lymphomas (PTCL) are relatively rare, heterogeneous, and therapeutically challenging. While significant therapeutic gains and improved understanding of disease pathogenesis have been realized for selected PTCL subtypes, the most common PTCL in North America remains "not otherwise specified (NOS)" and is an unmet need. However, improved understanding of the genetic landscape and ontogeny for the PTCL subtypes currently classified as PTCL, NOS have been realized, and have significant therapeutic implications, which will be reviewed here. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Reviewed by: Reuben Matthew Tooze, University of Leeds, United Kingdom; Anjali Mishra, Sidney Kimmel Cancer Center, United States; Brad Haverkos, University of Colorado Hospital, United States Edited by: Jean El Cheikh, American University of Beirut Medical Center, Lebanon This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology |
ISSN: | 2234-943X 2234-943X |
DOI: | 10.3389/fonc.2023.1101441 |